[{"id":"59cf1c76-20c0-482d-a704-e18624a0a2cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787613","created_at":"2023-03-28T14:05:08.783Z","updated_at":"2024-07-02T16:35:18.055Z","phase":"Phase 2","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","source_id_and_acronym":"NCT05787613","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ROS1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • ROS1 rearrangement • LAG3 expression","tags":["PD-L1 • ROS1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ROS1 rearrangement • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-02-22"},{"id":"da311a09-c528-4f05-95fc-0dd180af7950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400265","created_at":"2022-06-01T14:58:52.168Z","updated_at":"2024-07-02T16:35:20.637Z","phase":"Phase 1","brief_title":"Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor","source_id_and_acronym":"NCT05400265","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • HLX26"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-02-06"},{"id":"a814061c-a9d2-4cbb-9eda-0e4a4d034755","acronym":"","url":"https://clinicaltrials.gov/study/NCT05584137","created_at":"2022-10-18T14:57:08.195Z","updated_at":"2024-07-02T16:35:40.262Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC","source_id_and_acronym":"NCT05584137","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • HLX26"],"overall_status":"Suspended","enrollment":" Enrollment 49","initiation":"Initiation: 06/15/2023","start_date":" 06/15/2023","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-08-11"}]